Healthcare of Ontario Pension Plan Trust Fund Takes $26.35 Million Position in Urogen Pharma $URGN

Healthcare of Ontario Pension Plan Trust Fund bought a new stake in Urogen Pharma (NASDAQ:URGN) in the fourth quarter, Holdings Channel reports. The institutional investor bought 1,125,100 shares of the company’s stock, valued at approximately $26,350,000.

A number of other institutional investors and hedge funds have also made changes to their positions in URGN. AQR Capital Management LLC raised its holdings in shares of Urogen Pharma by 347.5% in the first quarter. AQR Capital Management LLC now owns 114,066 shares of the company’s stock valued at $1,262,000 after buying an additional 88,577 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Urogen Pharma by 7.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,320 shares of the company’s stock valued at $258,000 after buying an additional 1,653 shares during the last quarter. Jane Street Group LLC increased its stake in shares of Urogen Pharma by 94.3% during the first quarter. Jane Street Group LLC now owns 51,177 shares of the company’s stock worth $566,000 after acquiring an additional 24,839 shares during the period. Cetera Investment Advisers acquired a new position in shares of Urogen Pharma during the second quarter worth about $361,000. Finally, JPMorgan Chase & Co. increased its stake in shares of Urogen Pharma by 5.2% during the second quarter. JPMorgan Chase & Co. now owns 390,364 shares of the company’s stock worth $5,348,000 after acquiring an additional 19,405 shares during the period. 91.29% of the stock is owned by hedge funds and other institutional investors.

Urogen Pharma Trading Up 3.8%

Shares of URGN opened at $30.86 on Tuesday. The firm’s 50-day moving average is $25.96 and its two-hundred day moving average is $22.86. Urogen Pharma has a twelve month low of $12.61 and a twelve month high of $32.37. The firm has a market capitalization of $1.50 billion, a P/E ratio of -11.22 and a beta of 1.59.

Urogen Pharma (NASDAQ:URGN) last issued its earnings results on Thursday, May 7th. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.48) by $0.01. The company had revenue of $50.96 million for the quarter, compared to analyst estimates of $44.83 million. Analysts predict that Urogen Pharma will post -0.98 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. LADENBURG THALM/SH SH assumed coverage on shares of Urogen Pharma in a research note on Monday, May 11th. They set a “buy” rating and a $43.00 price target on the stock. Jefferies Financial Group upgraded shares of Urogen Pharma to a “strong-buy” rating in a research note on Friday, April 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Urogen Pharma in a research note on Monday, April 20th. D. Boral Capital reiterated a “buy” rating and set a $33.00 price target on shares of Urogen Pharma in a research note on Tuesday, March 31st. Finally, Oppenheimer reiterated an “outperform” rating on shares of Urogen Pharma in a research note on Tuesday, June 2nd. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Urogen Pharma currently has a consensus rating of “Moderate Buy” and an average price target of $39.50.

Insiders Place Their Bets

In other Urogen Pharma news, insider Mark Schoenberg sold 5,222 shares of the company’s stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $27.30, for a total transaction of $142,560.60. Following the transaction, the insider directly owned 139,763 shares in the company, valued at approximately $3,815,529.90. This represents a 3.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 4.80% of the company’s stock.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.